[Federal Register Volume 76, Number 181 (Monday, September 19, 2011)]
[Rules and Regulations]
[Pages 57906-57907]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2011-23874]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

21 CFR Parts 522 and 556

[Docket No. FDA-2011-N-0003]


New Animal Drugs; Gamithromycin

AGENCY: Food and Drug Administration, HHS.

ACTION: Final rule.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is amending the animal 
drug regulations to reflect approval of an original new animal drug 
application (NADA) filed by Merial, Ltd. The NADA provides for the 
veterinary prescription use of gamithromycin injectable solution for 
the management of bovine respiratory disease (BRD). FDA is also 
amending the regulations to add the established tolerances for residues 
of gamithromycin in edible tissues of cattle.

DATES: This rule is effective September 19, 2011.

FOR FURTHER INFORMATION CONTACT: Cindy L. Burnsteel, Center for 
Veterinary Medicine (HFV-130), Food and Drug Administration, 7500 
Standish Pl., Rockville, MD 20855, 240-276-8341, e-mail: 
[email protected].

SUPPLEMENTARY INFORMATION: Merial Ltd., 3239 Satellite Blvd., Bldg. 
500, Duluth, GA 30096-4640 filed NADA 141-328 that provides for the 
veterinary prescription use of ZACTRAN (gamithromycin), an injectable 
solution, in beef and non-lactating dairy cattle for the treatment of 
BRD associated with Mannheimia haemolytica, Pasteurella multocida, and 
Histophilus somni; and for the control of respiratory disease in beef 
and non-lactating dairy cattle at high risk of developing BRD 
associated with M. haemolytica and P. multocida. The application is 
approved as of June 16, 2011, and the regulations are amended in 21 CFR 
parts 522 and 556 to reflect the approval.
    A summary of safety and effectiveness data and information 
submitted to support approval of this application may be seen in the 
Division of Dockets Management (HFA-305), Food and Drug Administration, 
5630 Fishers Lane, rm. 1061, Rockville, MD 20852, between 9 a.m. and 4 
p.m., Monday through Friday.
    Under section 512(c)(2)(F)(i) of the Federal Food, Drug, and 
Cosmetic Act (21 U.S.C. 360b(c)(2)(F)(i)), this approval qualifies for 
5 years of marketing exclusivity beginning on the date of approval.
    The Agency has determined under 21 CFR 25.33 that this action is of 
a type that does not individually or cumulatively have a significant 
effect on the human environment. Therefore, neither an environmental 
assessment nor an environmental impact statement is required.
    This rule does not meet the definition of ``rule'' in 5 U.S.C. 
804(3)(A) because it is a rule of ``particular applicability.'' 
Therefore, it is not subject to the congressional review requirements 
in 5 U.S.C. 801-808.

List of Subjects

21 CFR Part 522

    Animal drugs.

21 CFR Part 556

    Animal drugs, Foods.

    Therefore, under the Federal Food, Drug, and Cosmetic Act and under 
authority delegated to the Commissioner of Food and Drugs and 
redelegated to the Center for Veterinary Medicine, 21 CFR parts 522 and 
556 are amended as follows:

PART 522--IMPLANTATION OR INJECTABLE DOSAGE FORM NEW ANIMAL DRUGS

0
1. The authority citation for 21 CFR part 522 continues to read as 
follows:

    Authority: 21 U.S.C. 360b.

0
2. Section 522.1014 is added to read as follows:

[[Page 57907]]

Sec.  522.1014  Gamithromycin.

    (a) Specifications. Each milliliter (mL) of solution contains 150 
milligrams (mg) gamithromycin.
    (b) Sponsor. See No. 050604 in Sec.  510.600(c) of this chapter.
    (c) Related tolerances. See Sec.  556.292 of this chapter.
    (d) Conditions of use--(1) Cattle--(i) Amount. Administer 6 mg/
kilogram of body weight (2 mL per 110 pounds) one time by subcutaneous 
injection in the neck.
    (ii) Indications for use. For the treatment of bovine respiratory 
disease (BRD) associated with Mannheimia haemolytica, Pasteurella 
multocida, and Histophilus somni in beef and non-lactating dairy 
cattle; and for the control of respiratory disease in beef and non-
lactating dairy cattle at high risk of developing BRD associated with 
M. haemolytica and P. multocida.
    (iii) Limitations. Cattle intended for human consumption must not 
be slaughtered within 35 days from the last treatment. Do not use in 
female dairy cattle 20 months of age or older. A withdrawal period has 
not been established for this product in preruminating calves. Do not 
use in calves to be processed for veal. Federal law restricts this drug 
to use by or on the order of a licensed veterinarian.
    (2) [Reserved]

PART 556--TOLERANCES FOR RESIDUES OF NEW ANIMAL DRUGS IN FOOD

0
3. The authority citation for 21 CFR part 556 continues to read as 
follows:

    Authority:  21 U.S.C. 342, 360b, 371.


0
4. Section 556.292 is added to read as follows:


Sec.  556.292  Gamithromycin.

    (a) Acceptable Daily Intake (ADI). The ADI for total residues of 
gamithromycin is 10 micrograms per kilogram of body weight per day.
    (b) Tolerances. The tolerances for gamithromycin (the marker 
residue) are:
    (1) Cattle--(i) Liver (the target tissue): 500 parts per billion 
(ppb).
    (ii) Muscle. 150 ppb.
    (2) [Reserved]
    (c) Related conditions of use. See Sec.  522.1014 of this chapter.

    Dated: September 13, 2011.
Bernadette Dunham,
Director, Center for Veterinary Medicine.
[FR Doc. 2011-23874 Filed 9-16-11; 8:45 am]
BILLING CODE 4160-01-P